MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on September 10, 2004; DOI: 10.1124/mol.104.000166


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.000166v1
66/6/1617    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Val J. Watts
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vortherms, T. A.
Right arrow Articles by Watts, V. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vortherms, T. A.
Right arrow Articles by Watts, V. J.


Received for publication March 8, 2004.
Revised September 3, 2004.
Accepted for publication September 10, 2004.

Using molecular tools to dissect the role of G{alpha}s in sensitization of AC1

Timothy A. Vortherms 1, Chau H. Nguyen 1, Catherine H. Berlot 2, Val J. Watts 1*

1 Purdue University 2 Geisinger Clinic

* Address correspondence to: E-mail: wattsv{at}pharmacy.purdue.edu

Abstract

Acute activation of G{alpha}i/o-coupled receptors inhibits adenylyl cyclase, whereas persistent activation of G{alpha}i/o-coupled receptors results in a compensatory sensitization of adenylyl cyclase activity following subsequent activation by G{alpha}s or forskolin. Several indirect observations have suggested the involvement of increased G{alpha}s-adenylyl cyclase interactions in the expression of sensitization, however, evidence supporting a direct role for G{alpha}s has not been well established. In the present report, we have used two genetic approaches to further examine the role of G{alpha}s in heterologous sensitization of Ca2+-sensitive type 1 adenylyl cyclase (AC1). In the first approach, we constructed G{alpha}s-insensitive mutants of AC1 (F293L and Y973S) that retained sensitivity to Ca2+ and forskolin activation. Persistent (2 h) activation of the D2 dopamine receptor resulted in a significant augmentation of basal or Ca2+- and forskolin-stimulated AC1 activity, however, sensitization of G{alpha}s-insensitive mutants of AC1 was markedly reduced compared to wild-type AC1. In the second strategy, we examined the requirement of an intact receptor-G{alpha}s signaling pathway for the expression of sensitization using dominant negative G{alpha}s mutants ({alpha}3{beta}5 G226A/A366S or {alpha}3{beta}5 G226A/E268A/A366S) to disrupt D1 dopamine receptor activation of recombinant AC1. D1 dopamine receptor-G{alpha}s signaling was attenuated in the presence of {alpha}3{beta}5 G226A/A366S or {alpha}3{beta}5 G226A/E268A/A366S, but D2 agonist-induced sensitization of Ca2+-stimulated AC1 activity was not altered. Together, the present findings directly support the hypothesis that the expression of sensitization of AC1 involves G{alpha}s-adenylyl cyclase interactions.


Key words: Dopamine, Gi family, Gs family, Adenylyl cyclases, cAMP, G protein regulation, Drug tolerance/dependence





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics